Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
US9822065B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9822065-B1 |
| Application number | US-201715432859-A |
| Country | US |
| Kind code | B1 |
| Filing date | Feb 14, 2017 |
| Priority date | Mar 6, 2015 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R 1 to R 4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of 2-amino-8-methoxycarbonyl-3H-1-benzazepine-4-carboxylic acid (I) comprising the step of deprotection of 4-tert-butyl 8-methyl 2-amino-3H-benzo[b]azepine-4,8-dicarboxylate (II) under acidic conditions. 2. The process according to claim 1 said process further comprising the step of reductive cyclization of compound (III) by treating compound (III) with iron and acetic acid. 3. The process according to claim 2 said process further comprising condensation of tert-butyl 3-cyano-2-(triphenylphosphoranylidene)propanoate with methyl 4-formyl-3-nitrobenzoate under basic conditions to afford methyl 4-(3-(tert-butoxy)-2-(cyanomethyl)-3-oxoprop-1-en-1-yl)-3-nitrobenzoate 4. A process for the preparation compound according to formula (VI) comprising condensation of VIII with VII basic conditions to afford methyl 4-(3-(tert-butoxy)-2-(cyanomethyl)-3-oxoprop-1-en-1-yl)-3-nitrobenzoate wherein R a and R b are C 1-6 alkyl or benzyl. 5. A compound which compound is 2-amino-8-methoxycarbonyl-3H-1-benzazepine-4-carboxylic acid, 4-tert-butyl 8-methyl 2-amino-3H-benzo[b]azepine-4,8-dicarboxylate or tert-butyl 3-cyano-2-(triphenylphosphoranylidene)propanoate.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunomodulators · CPC title
specific for metastasis · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.